A panel of the European medicines regulator has recommended approving an eco-friendly version of AstraZeneca's inhaler for the treatment of a chronic lung condition, the drugmaker said on Friday.

AstraZeneca PLC closed 18.54% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The company plans to invest billions in a new drug manufacturing hub in Virginia, dedicated to chronic disease treatments, alongside additional facilities in California, Indiana, Maryland, ...

AstraZeneca PLC closed 20.27% below its 52-week high of £133.88, which the company reached on September 3rd.

The announcement by AstroZeneca follows a growing trend of companies pledging to invest in pharmaceutical manufacturing on American soil in pursuit of appeasing President Donald Trump as he threatens ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

Xelix, a leading agentic AI software company in the Accounts Payable (AP) space, today announced a $160 million Series B ...